<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780062</url>
  </required_header>
  <id_info>
    <org_study_id>PETEChIA</org_study_id>
    <nct_id>NCT03780062</nct_id>
  </id_info>
  <brief_title>Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet</brief_title>
  <acronym>PETEChIA</acronym>
  <official_title>Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All the patients admitted in emergency department for minor traumatized cranial, with
      antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias.
      If they are agree, a blood sample for the dosage of S100b will be done.

      No other modification of the medical care, all patients will have tomodensitometria,
      according with recommendations. The aim of the study is to validate the negative predictive
      value of S100b in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Minor Traumatic Brain Injury</condition>
  <condition>Treatment by Antiplatelet</condition>
  <arm_group>
    <arm_group_label>S100B protein dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S100B protein dosing</intervention_name>
    <description>Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L</description>
    <arm_group_label>S100B protein dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 Years old

          -  Minor traumatic brain injury measured by a Glasgow score between 13 and 15

          -  Antiplatelet agent therapy

          -  Free subject without tutorship or curatorship

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Glasgow score &lt;13

          -  Traumatic brain injury older than 6 hours

          -  Patient without any social security system

          -  Patient with renforced protection (tutorship, curatorship, …)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jérémy GUENEZAN, Hospital Practitioner</last_name>
    <phone>0549444444</phone>
    <phone_ext>46991</phone_ext>
    <email>jeremy.guenezan@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU of MONTPELLIER</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha SEBBANE, Professor</last_name>
      <phone>0467336733</phone>
      <email>m-sebbane@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU of NICE</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques LEVRAUT, Professor</last_name>
      <phone>0492033242</phone>
      <email>levraut.j@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Pité Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Laure PAQUET, Hospital Practitionner</last_name>
      <phone>0142176006</phone>
      <email>annelaure.paquet@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU of POITIERS</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémy GUENEZAN, Hospital Practitionner</last_name>
      <phone>0549444444</phone>
      <phone_ext>46991</phone_ext>
      <email>jeremy.guenezan@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S100B protein</keyword>
  <keyword>minor traumatic brain injuries</keyword>
  <keyword>antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

